



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
KLEEMANN, et al.

Examiner:

Art Unit: 1614

Application No.: 10/749,630

Filed: December 31, 2003

Title: **3-Guanidinocarbonyl-1-heteroaryl-indole
Derivatives, Preparation process, Their Use as
Medicaments, and Pharmaceutical
Compositions Comprising Them**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as First
Class Mail in an envelope addressed to Commissioner
for Patents, P.O. Box 1450, Alexandria, VA 22313-
1450, on

February 3, 2005
Date of Deposit
Gene M. Harris
Signature

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Mail Stop
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.


- ☒ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

- ☐ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☐ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

A concise explanation of the relevance of some or all of the items listed on the attached PTO-1449 (modified) is as follows:

The reference Joh. Howitz et al. "Über o-, p- und ana- Jodchinolin und deren Derivate" has been cited in the application text and provided herewith, because this reference describes a method with which 8-Iodoquinoline can be prepared. 8-Iodoquinolin has been used as an educt for the preparation of, for example, Example 9 in the present application.

Respectfully submitted,



Joseph Rossi / Reg. No. 47,038
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3410
Telefax (908) 231-2626
Aventis Docket No. DEAV2002/0095 US CNT

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/749,630
				Filing Date	12-31-2003
				First Named Inventor	KLEEMANN
				Group Art Unit	1614
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	DEAV2002/0095 - US - CNT

[illegible]

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴ <i>(if known)</i>				
		EP	0622356		KOJIMA, et al.	11-02-1994	
		WO	95/22524		BITONTI, et al.	08-24-1995	
		WO	99/43663		HAMANAKA, et al.	09-02-1999	
		WO	00/71537		KARABELAS, et al.	11-30-2000	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/CSS (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/749,630		
		Filing Date	12-31-2003		
		First Named Inventor	KLEEMANN		
		Group Art Unit	1614		
		Examiner Name			
Sheet	2	of	2	Attorney Docket Number	DEAV2002/0095 - US - CNT

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		EVERETT, Chris, Haemolytic disease of the newborn - time to prevent unnecessary deaths, Comparative Medicine, The British Journal of General Practice, 2000, 50 (5), pg. 511	
		HOWITZ, et al., Uber O, p- und ana-Jodchinolin und deren Derivate, Justus Liebigs Ann. Chem. (1913), 396, pgs. 53-75	
		SCHULTHEIS, Patrick, et al., Targeted Disruption of the Murine Na ⁺ /H ⁺ Exchanger Isoform 2 Gene Causes Reduced Viability of Gastric Parietal Cells and Loss of Net Acid Secretion, J. Clin. Invest., 1998, 101 (6), pps. 1243-1253	
		SUI, Z. et al., A Convenient Synthesis of 3,5-Bis(Trifluoromethyl) Salicylic Acid, Synthetic Communications, 1997, 27(20), pp.3581-3590	
		TOYOTA, Masahiro, et al., Tandem Michael Addition-[3,3] Sigmatropic Rearrangement Processes, Part 2. Constuction of Cyclopropa [3,4] pyrrolo [3,2-e] indol-4-one (CPI) Unit of Antitumour Antibiotic CC-1065, J. Chem. Soc. Perkin Trans. 1, (1992), (5), pgs. 547-552	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPFP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.